Evidence map›Paper›PMID 41074162›Full record

ArticleJournal of nanobiotechnology2025

Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation.

Jinchao Zhao, Lei Lei, Cheng Zeng, Xianfei Zhou, Junkang Ding, Wenbin Dai, Angfeng Jiang, Shaomin Zou, Qiao Jin, Zhe Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinchao Zhao *Department of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Lei Lei *Department of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Cheng Zeng *Department of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Xianfei ZhouDepartment of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Junkang DingDepartment of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Wenbin DaiMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China.
Angfeng JiangDepartment of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Shaomin ZouDepartment of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Qiao JinMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China. jinqiao@zju.edu.cn.
Zhe TangDepartment of General Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. 8xi@zju.edu.cn.

Funding

the National Natural Science Foundation of China 52473152the National Natural Science Foundation of China 82204660the "Pioneer" and "Leading Goose" R&D Program of Zhejiang 2025C02132
6 · The paper itself

Abstract

Incomplete radiofrequency ablation (iRFA) of hepatocellular carcinoma (HCC) has the risk to exacerbate the tumor immunosuppressive microenvironment and promote lung metastasis. There is an urgent need to reverse the immunosuppressive microenvironment and reduce lung metastasis after iRFA. Herein, an iron-based metal-organic framework loaded with capmatinib (Fe-MOF/Cap) is employed to reverse the immunosuppressive microenvironment dominated by M2-like tumor-associated macrophages (TAMs) after iRFA and inhibit lung metastasis of HCC. On one hand, Fe-MOF/Cap repolarizes M2-like TAMs to M1-like TAMs and inhibits the expression of PD-L1 after iRFA, promoting CD8

Indexed as

BenzamidesCarcinoma, HepatocellularImidazolesLiver NeoplasmsLung NeoplasmsNeoplasm MetastasisRadiofrequency AblationTriazinesAnimalsCell Line, TumorCell PolarityImmune ToleranceIronMaleMetal-Organic FrameworksMiceBenzamidescapmatinibImidazolesIronMetal-Organic FrameworksTriazinesDrug deliveryIncomplete radiofrequency ablationIron-based metal-organic frameworkTumor immunosuppressive microenvironmentTumor metastasis

Identifiers

PMID41074162
PMCPMC12514822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.